Future experiments will be necessary to determine the exact role of CheF in archaeal flagellar motor switching. Methods Strains and growth conditions H. salinarum strains R1 (DSM 671) and S9 [71] were grown aerobically either in complex medium or in synthetic medium as described previously [72, 73]. Transformed cells were grown with 10 μg ml-1 mevinolin or 0.15 μg ml-1 novobiocin. Transformation of H. salinarum was performed essentially as described by [74]. E. coli strain DH5α and transformants were grown in LB medium at 37°C and supplemented with ampicillin (100 μg ml-1), kanamycin (25 μg ml-1), or chloramphenicol (50 μg ml-1), if necessary. Protein-protein

interaction analysis Interactions between halobacterial proteins were determined Talazoparib purchase by affinity purification of halobacterial protein complexes using bait proteins fused to a cellulose-binding domain. Components

of the complex were identified by mass spectrometry. Additional file 1 provides a detailed description of this method. Construction of in frame deletion mutations In-frame deletion plasmids were constructed using the vectors pMKK100 [50] and pMS3 (unpublished). All PCR reactions were done with Phusion Polymerase according to supplier’s instructions and genomic DNA of H. salinarum strain R1 as template. 500 bp of sequence upstream (us) and downstream (ds) of the targeted gene were amplified by PCR using the primers listed in Additional file 7. The corresponding PCR Phosphoprotein phosphatase products were used as templates in see more a second PCR using the external primers (us_fo and ds_re), resulting in a fusion product of us and ds sequence. The fusion products were ligated

into both pMS3 and pMKK100, and the resulting deletion plasmids verified by DNA sequencing of the insert. Deletion mutants were generated by transformation of the deletion plasmids into the wild type strains R1 and S9 and subsequent cultivation without selection pressure as described in [50]. Briefly, after transformation and plating on X-gal and antibiotic containing plates two blue clones were picked and grown in complex medium without antibiotics. After three passages of the culture, roughly 600 cells were plated on X-gal containing plates without antibiotics. Red colonies (red color indicates that these cells have lost the integrated plasmid) were inoculated into complex medium and screened for the loss of the target gene by PCR using the primers spanning the flanking regions. Southern blot analysis Deletions were verified by Southern blot analysis. Genomic DNA of wild type and deletion strains was isolated and digested with BglI. DIG-labeled DNA probes were generated via PCR amplification of the upstream or the gene sequence from genomic DNA in the presence of DIG-11-dUTP (Roche).

Figure 3 DSC-determined onset temperatures and energy release values for Al/NiO MIC with different NiO ratios. The dependence of the onset temperatures on the NiO ratios of the composites is shown in Figure 3. It can be observed that increasing the NiO ratio Veliparib supplier did not significantly change the onset temperature of the exothermic peak. This indicates a narrow size distribution of Al nanoparticles in these composites and sufficient intermixing between Al nanoparticles and NiO nanowires.

All measured onset temperatures are smaller than the melting temperature of bulk Al. In the literature, it was suggested that the activation energy of the thermite reaction depends on the diffusion distance over which these metal ions FK506 clinical trial (aluminum and nickel which become available from the decomposition of NiO) need to travel before initiating the reaction [46]. To quantify the activation energy of the Al nanoparticle and NiO nanowire composites, the DSC curves of sample D was processed directly using the TA software and through the implementation of the American Society for Testing and Materials E698 method. Note that the ASTM method is often the only effective approach to analyze reactions with multiple exotherms because these peak temperatures at different heating rates are not significantly influenced by the baseline shift [47]. The ASTM E698 method generally gives an accurate assessment

of the activation energy. However, calculations Lonafarnib of the pre-exponential factor (Z) assume the nth order reaction behavior. The derived activation energies for sample D are 216.3 and 214.5 kJ/mol, respectively, from two methods. Figure 4 shows the procedure

to determine the activation energy from the DSC data when the kinetic rate was expressed as a function β(T) of the temperatures T max corresponding to the maximum heat flow. The derived activation energy agrees generally with the previously reported activation energies for Al nanoparticle-based thermite composites (such as, 248, 222, and 205 kJ/mol for the Al-Fe2O3, Al-Bi2O3, and Al-MnO3, respectively [48]). The activation energy of the Al nanoparticle and NiO nanowire MIC is close to but lower than the reported activation energy of the NiO reduction process (277 KJ/mol [49]). Taking into account the size effect on the reactivity of NiO nanowires, this ignition energy may indicate a thermal decomposition of NiO about the onset temperature of the studied MIC, which behaves similarly to the ignition of the Al-Bi2O3 MIC [50]. Meanwhile, for heterogeneous condensed phase MICs, the limiting factor affecting the ignition event can also be the solid-phase diffusion. Further investigations on the ignition mechanism of the Al/NiO MIC are expected. Figure 4 Graph used for determining the activation energy of sample D, 33 wt.% NiO, using ASTM E698 method. The XRD analysis was performed on the reaction products from sample D which was a fuel-rich MIC with Φ = 3.5.

This indicates that MWNT inhibits the development of smaller/younger GPCR Compound Library research buy vessels only. Our report is consistent with the results of another study showing that pristine MWNT displayed an anti-angiogenic effect on an in vivo VEGFA/bFGF-induced model [33] and in in vitro HUVEC

tubule formation assays [34]. However, doxorubicin conjugated with single-wall nanotubes had the opposite effects [35]. As expected, nanoparticles had less impact on the development of older vessels. Only ND, which exerted the strongest anti-angiogenic properties, induced a significant decrease in vessel length and the number of branch points. However, ND did not change the area of older vessels (100 to 200 μm). Reduced length and branching without significant changes in vessel area suggest that see more ND can inhibit the development of vessels with dimensions that slightly exceed 100 μm and smaller. The present results give new insights into the bioactive properties of ND and clearly show that this carbon nanoparticle can be considered for use in low-toxicity

anti-angiogenic therapy. Interestingly, our results demonstrated pro-angiogenic activity of pristine C60, which increased the number of branch points and vessel length. Fullerene C60 has been used to inhibit cancer growth [36] and is used as photosensitisers in photodynamic therapy [37]. However, Zogovic et al. [38] studied the effect of nanocrystaline fullerene on melanoma tumour and showed that fullerene, probably by immunosuppression, had tumour-promoting activity and increased the production of nitric oxide (NO), which can promote angiogenesis [39].

Furthermore, other reactive oxygen species can Methane monooxygenase also induce angiogenesis [40]. The ability of C60 to generate reactive oxygen species has been previously demonstrated [41, 42]. NO promotes angiogenesis by up-regulating the expression of the VEGFA receptor [43], which is consistent with our report. This appears to be the most probable mechanism underlying fullerene pro-angiogenic effects and may only be specific for pristine nanoparticles. Hydroxylated C60 has been shown to protect cells in vitro form oxidative stress, while pristine nanoparticles show pro-oxidant capacity [44, 45]. Moreover, C60 modified with multihydroxylated metal can simultaneously down-regulate more than ten angiogenic factors and significantly decrease the capillary vessels of tumours (average size 1.2 cm in diameter) [46]. Murugesan et al. [33] demonstrated that pristine MWNT and C60 inhibited the angiogenesis induced by exogenous VEGFA or bFGF. Our results indicated that C60 had the opposite effect on vessels not stimulated by exogenous pro-angiogenic factors. This suggests that C60 can have both anti- and pro-angiogenic activity depending on the physiological state of blood vessels. Conclusions We compared the anti-angiogenic properties of pristine carbon nanomaterials.

Especially,

the poultry-associated BAPS cluster 1 was very heterogeneous; Fulvestrant in vitro the ST-45 CC was most common and grouped together with several uncommon, unrelated clonal complexes, often not found in our poultry isolates. In our previous study [25], the ST-45 CC found in our human isolates was associated with tasting of raw or undercooked meat as well as contact with dogs or cats. Also, the ST-45 CC has been found from penguins on the Antarctic [37], implying that this CC has a wide host range and is environmentally well adapted. The ST-22, ST-42 and ST-48 CCs, which were grouped together with the ST-45 CC in BAPS cluster 1, have been commonly found in companion animals in other studies [11, 28, 38]. However, more studies are needed to establish the role of environmental contamination sources serving as C. jejuni vectors for both human infection and chicken colonization. Most admixture was found in clusters 1 and 4 with the majority of admixed STs being novel and associated with

the bovine isolates. All admixed STs with the highest posterior probability in cluster 1 (poultry-associated) were admixed with cluster 4 (bovine-associated) and most of these STs were found only in bovine isolates. In contrast, most admixed STs with the highest posterior probability in cluster 4 were admixed with clusters 2 and 3, in which only human isolates were assigned to NVP-LDE225 solubility dmso and mostly contained uncommon, unassigned STs. These findings could imply that recombination is more common in STs specific to bovines, which is supported by the high diversity of our bovine isolates. Bovines have a longer life-span than poultry and persistence of C. jejuni clones in herds and specific bovine-associated lineages imply that these strains can adapt to long-lasting colonization, thereby increasing the chance of horizontal transfer of genetic material and recombination. The ST-61 CC was found as a separate cluster (cluster 5) by BAPS, with C-X-C chemokine receptor type 7 (CXCR-7) the exception of ST-618 (cluster 4, admixed with cluster

1). This finding was not surprising since the ST-61 CC is known to have imported C. coli alleles (e.g. uncA17) and therefore is phylogenetically less related to other C. jejuni clonal complexes [39]. Both ST-618 and ST-3509 do not possess the uncA17 allele, but ST-3509 carries the uncA38 allele. This allele is common in both the ST-61 CC and the C. coli related ST-828 CC and likely the presence of this allele caused ST-3509 to be included in BAPS cluster 5. ST-618, however, carries the uncA5 allele, which is commonly found in both the ST-21 CC (cluster 4) and the ST-48 CC. This explains why this particular ST was grouped together with the ST-21 CC and at the same time admixed with cluster 1. These results demonstrate that the import of C. coli DNA can have a large impact on the MLST analysis of C. jejuni strains and this should be taken into account in source attribution studies.

Figure 8 Magnetization curve. (a) Fe3O4 (b) Fe3O4@SiO2, and (c) Fe3O4@SiO2-OCMCS-FA nanovehicle at 300 K. In vitro targeting of nanovehicle The ability of nanoparticles to target specific locations is one of the most important factors for their prospective application in drug delivery and biomedicine. To investigate the uptake possibility of Fe3O4@SiO2-OCMCS-FA, CLSM was applied to trace the process of this nanovehicle. Therefore, RB is labeled on the surface of the nanovehicle to distinguish it. To explore the practical application of this nanovehicle in the targeting of tumor cells, the

particles were incubated in physiological conditions with HeLa cells bearing the over-expressed Selleck LY2606368 folate receptor. Figure 9 shows DAPI, LBH589 supplier RB, and merged images of HeLa cells incubated with RBFe3O4@SiO2 (20 μg mL-1, control) and RBFe3O4@SiO2-OCMCS-FA (20 μg mL-1) for 2 h. Interestingly,

even at the very low concentration, the CLSM images show that the RBFe3O4@SiO2-OCMCS-FA nanoparticles could be taken up by HeLa cells within a short period as manifested by the appearance of spot-like red fluorescence in cells (Figure 9b), while untreated RBFe3O4@SiO2 showed negligible background fluorescence under similar imaging conditions (Figure 9a). The merge of the bright-field and fluorescent images further demonstrates that the luminescence is strongly correlated with the intracellular location (Figure 9b) suggesting the feasibility and efficiency of the nanoparticles for

anticancer drug delivery into cancer cells. In addition, the fluorescent image shown in Figure 9b also testifies that the nanovehicle was mainly distributed in the cytoplasm after cellular uptake. The confocal laser scanning microscope observation confirms that the nanovehicle could be effectively taken up by the HeLa cells as the folate modified. Figure 9 Confocal laser scanning microscope images of subcellular Flavopiridol (Alvocidib) localization. (a) RBFe3O4@SiO2 and (b) RBFe3O4@SiO2-OCMCS-FA after 2 h of incubation with HeLa cells. Nuclei were stained with DAPI. To further reveal that the nanovehicle was internalized in HeLa cells rather than being bound to the cell surface, bio-TEM was used to analyze the nanovehicle-treated cells. Unlike the untreated cells (Figure 10a), some aggregates of nanovehicles were observed as black patches inside the cell cytoplasm which maintained their core-shell structure (Figure 10b and the inset), while no nanovehicle was found in the nucleus which coincided with the results of CLSM. Based on the cell morphology, it is plausible that the nanovehicle accumulates on the membrane (Figure 10c) by the high specific interaction between folic acid on the nanovehicle and FR on HeLa cells which may increase the uptake through folate receptor-mediated endocytosis.

This may be overcome by using an intercalating reporter dye in place of a fluorescent probe as a qPCR reporter

mechanism; however, the loss of tertiary-level of specificity is a potential concern in direct application of an intercalating dye assay to specimens containing high amounts of nontarget DNA. Exogenous bacterial DNA, particularly from biologically synthesized reagents such as Taq DNA polymerase are a known limitation for analyzing samples with low bacterial load [28, 33]. Recently, this issue has received renewed attention due to increased usage of next-generation sequencing and the frequent data contamination from exogenous bacterial DNA. Several methods have been evaluated for removing bacterial contaminants from Taq DNA polymerase, including UV irradiation [34, 35], DNAse I treatment, and ultrafiltration [36]. The level of E. coli contamination in Taq DNA polymerase has been estimated at 102 to 105 genome Trametinib equivalents MAPK Inhibitor Library ic50 of bacterial DNA per unit of enzyme [28]. This is consistent with the lowest amount of contamination we have observed in our experiments, which were 5 and 10 copies of 16 S rRNA gene in 5 μl and 10 μl reactions, respectively. The ubiquity of bacterial DNA also makes the determination of assay specificity challenging. Our use of qPCR-quantified plasmid standards addressed a major limitation in the preparation of qPCR quantification standards. The

conventional approach of quantifying bacterial genomic DNA or plasmid Avelestat (AZD9668) standards necessitates converting mass (i.e., nanograms per μl) to copy number (i.e., 108 copies per μl) and can introduce substantial error. Thus far, we have also successfully applied BactQuant to a diverse range of clinical specimens, including swab eluents, surgical specimens, and respiratory specimens, but we did not present these findings in this paper. To fully understand the likelihood of false negative results

due to interference from human DNA or BactQuant’s limit of detection will require additional evaluations. Conclusion In summary, we have developed and evaluated a new broad-coverage qPCR assay—BactQuant—for bacterial detection and quantification that showed concurrently improved assay coverage and favorable quantitative parameters. Laboratory tests showed that in vitro performance was even better than predicted in the in silico analysis; however, our approach of evaluating assay coverage by considering the primer and probe sequences as a single unit is appropriate and necessary. In addition, when employing a copy number estimation method, such as qPCR, the quantification of standards is critical for accurate template quantification. Thus, our approach of quantifying plasmid standards using the intrinsic property of real-time PCR is another important step for any absolute quantification experiments using qPCR.

In the SA1891 mutant (N cls2), the CL level decreased, but not completely. In the double mutant (N cls1/cls2), the CL signal was undetectable, and the phosphatidylglycerol (PG) signal was increased. Hormones antagonist This is consistent with the CL synthesis pathway. An identical result was observed in the mutants derived

from S. aureus RN4220, 8325-4, SH1000, and MT01 (data not shown). These data strongly suggest that both SA1155 and SA1891 are CL synthase genes, and thus we refer to them as cls1 and cls2, respectively. Figure 3 Lipid synthesis pathway in S. aureus (modified from the KEGG pathway database). SA1155 (cls1) and SA1891 (cls2) are homologs of the B. subtilis cls gene. Figure 4 Phospholipid composition of N315 and its isogenic cls mutants. Cells were harvested during stationary phase. The means and standard deviations of relative signal intensities are shown at the bottom. Importance of CL for long-term survival under high salinity Given that CL plays a regulatory role during cell replication and division in E. coli [28, 31, 32], we investigated

the role of the cls genes in cells during growth phase transitions Abiraterone nmr in 0.1% NaCl LB (Figure 5). Mutation of the cls genes did not affect the growth curve until 47 h (Figure 5A), after which the cls1/cls2 double mutant showed slightly lower optical density. However, stationary-phase CFU numbers did not differ significantly between the cls1/cls2 double mutant and the parent strain (Figure 5B). Moreover, the CFU numbers were sustained in both strains until at least 700 h post-inoculation (data not shown). We conclude that CL is not necessary for cell growth and stationary phase survival of S. aureus under these conditions. Figure 5 Growth and stationary-phase survival under low salinity. Cells were grown in 0.1% NaCl LB. A : Growth was monitored by optical density (OD) measurements. N315: filled diamonds; cls1 mutant: filled squares; cls2 mutant: filled triangles; cls1/cls2 double mutant: open circles. Optical densities were checked at least twice, and the means are shown. After 47 h, the OD of only N315 and its cls1/cls2 double mutant were measured.

B : Number of CFUs during Demeclocycline the long incubation. The means and standard deviations of at least three independent experiments are shown. C : Thin-layer chromatography of phospholipids. Cells were harvested at 23 h. The phospholipid profile was confirmed to be similar up to 153 h (data not shown). The means and standard deviations of relative signal intensities from two independent experiments are shown on the right. In a high-salinity medium (15% NaCl LB), the growth yield was reduced in N315 and cls mutants (Figure 6A), but the growth of cls mutants was not significantly different from that of the parent strain. In contrast, the number of cls1/cls2 double mutant CFUs was drastically reduced after ~105 to 153 h in high-salinity medium (Figure 6B).

Evaluation of immunohistochemistry

was independently carried out by two investigators (K.S. and Selleckchem Alvelestat I.S.) who were unaware of the clinical data or disease outcome. In cases in which the results of immunohistochemical expression differed between the two observers, slides were evaluated by a third observer (S.N.). For Twist, cytoplasmic immunoreactivity was scored by its extent and intensity. Staining intensity was graded as follows: negative (0), weak (1), moderate (2) and strong (3). Staining extent was rated according to the percentage of positive cells. Samples with no stained tumor cells were rated as 0, those with < 25% of stained tumor cells were rated as 1, those with 25-50% of stained tumor cells were rated as 2, those with 50-75% of stained tumor cells were rated as 3 and those with > 75% of stained tumor cells were rated as 4. The results of staining intensity and extent

gave an overall staining score. An overall staining PF-02341066 in vivo score of 0-5 and 6-7 were regarded as low and high Twist expression, respectively. For E-cadherin, cancer cells were divided into two groups: preserved expression, which indicates cells with the same level of expression as that of normal epithelium distant enough from tumor, and reduced expression, which indicates cells with weak or absent expression compared with normal epithelium (Fig. 1) [7]. To evaluate expression of Twist and E-cadherin, ten fields (within the tumor and at the invasive front) were selected and expression in 1000 tumor cells (100 cells/field) was evaluated using high-power (×200) microscopy. Figure 1 Expression of Twist and E-cadherin proteins in ESCCs.

(A) High expression of Twist. (B) Weak expression of Twist. (C) Negative expression of Twist. (D) Preserved expression of E-cadherin is detected in the cancer adjacent normal tissue. (E) Preserved expression of E-cadherin. (F) Reduced expression of E-cadherin (Original magnification, ×400). Statistical analysis Statistical analysis of group differences this website was done using the X2 and Wilcoxon tests. The Kaplan-Meier method was used for survival analysis and differences in survival were estimated using the log-rank test. Prognostic factors were examined by univariate and multivariate analyses (Cox proportional hazards regression model). P < 0.05 was considered to be statistically significant. All statistical analyses were done with the software package JMP 5 for Windows (SAS Institute, Inc., Cary, NC). Results Expressions of Twist and E-cadherin in esophageal squamous cell carcinoma Twist expression was observed in the cytoplasm of cancer cells in 42.0% of all patients (70 of 166; Fig. 1A). E-cadherin expression was observed on the cell membrane of cancer cells, indicating preserved expression, in 40.4% of all patients (67 of 166; Fig. 1B).

PubMedCrossRef 15. Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer 2006, 13:293–325.PubMedCrossRef 16. Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001, 61:2505–2512.PubMed 17. Abdel-Fatah TM, Powe DG, Agboola J, Adamowicz-Brice

M, Blamey RW, Lopez-Garcia MA, Green AR, Reis-Filho JS, Ellis IO: The biological, clinical and prognostic Idasanutlin supplier implications of p53 transcriptional pathways in breast cancers. J Pathol 2010, 220:419–434.PubMed 18. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM: Estrogen receptor α inhibits p53 mediated transcriptional repression: implications for

the regulation of apoptosis. Cancer Res 2007, 67:7746–7755.PubMedCrossRef 19. Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, Ichimura K, Caldas C, Collins VP, Neal DE, Kelly JD: High resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 ( MDM4 ) as an amplification target exclusive of MDM2 and PT53. Clin Cancer Res 2008, 14:2527–2534.PubMedCrossRef Bortezomib concentration 20. Ding SL, Sheu LF, Yu JC, Yang TL, Chen BF, Leu FJ, Shen CY: Abnormality of the DNA double strand-break checkpoint/repair genes, ATM, BRCA1 and TP53 , in breast cancer is related to tumour grade. Br J Cancer 2004, 90:1995–2001.PubMedCrossRef 21. Rahko E, Blanco G, Bloigu R, Soini

Y, Talvensaari-Mattila A, Jukkola A: Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients — the role of p53. Breast 2006, 15:69–75.PubMedCrossRef PRKD3 22. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R: TP53 mutation and p53 overexpression for prediction of response to neo-adjuvant treatment in breast cancer patients. Clin Cancer Res 2000, 6:50–56.PubMed 23. Johnson KR, Fan W: Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. Anticancer Res 2002, 22:3197–3204.PubMed 24. Noguchi S: Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006, 97:813–820.PubMedCrossRef 25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177–182.PubMedCrossRef 26. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132–4141.PubMed 27. Morrow PKH, Zambrana F, Esteval FJ: Advances in systemic therapy for HER2-positive metastatic breast cancer.

CrossRefPubMed 2. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for ICG-001 cancer of the head of the pancreas. 201 patients. Ann Surg 1995, 221: 721–731. discussion 731–723CrossRefPubMed 3. Klinkenbijl JH,

Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230: 776–782. discussion 782–774CrossRefPubMed 4. Levin B, ReMine WH, Hermann RE, Schein PS, Cohn I Jr: Panel: cancer of the pancreas.

Am J Surg 1978, 135: 185–191.CrossRefPubMed 5. Crile G Jr: The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 1970, 130: 1049–1053.PubMed 6. Billingsley JS, Bartholomew LG, Childs DS Jr: A study of radiation therapy in carcinoma of the pancreas. Proc Staff Meet Mayo Clin 1958, 33: 426–430.PubMed 7. Rich TA: Radiation therapy for pancreatic cancer: eleven year experience at the JCRT. Int J Radiat Oncol Biol Phys 1985, 11: 759–763.CrossRefPubMed 8. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group Cancer 1985, 56: 2563–2568. 9. Moertel CG, Frytak S, Hahn RG, O’Connell Bafilomycin A1 order MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, et al.: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48: 1705–1710.CrossRefPubMed

10. Kawakami H, Uno T, Isobe K, Ueno N, Aruga T, Sudo K, Yamaguchi T, Saisho H, Kawata T, Ito H: Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2005, 62: 1357–1362.CrossRefPubMed 11. Gunderson LL, Martin JK, Kvols LK, Nagorney DM, Fieck JM, Wieand tetracosactide HS, Martinez A, O’Connell MJ, Earle JD, McIlrath DC: Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1987, 13: 319–329.CrossRefPubMed 12. Shipley WU, Wood WC, Tepper JE, Warshaw AL, Orlow EL, Kaufman SD, Battit GE, Nardi GL: Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg 1984, 200: 289–296.CrossRefPubMed 13. Tuckson WB, Goldson AL, Ashayeri E, Halyard-Richardson M, DeWitty RL, Leffall LD Jr: Intraoperative radiotherapy for patients with carcinoma of the pancreas. The Howard University Hospital experience, 1978–1986. Ann Surg 1988, 207: 648–654.CrossRefPubMed 14.